Print

IGBA commentary on FDA’s Draft Guidance on Labeling for Biosimilar Products

Brussels, June 3, 2016 –  IGBA thanks the Agency’s for providing an opportunity to comment on the Agency’s Draft Guidance on Labeling for Biosimilar Products (Docket No. FDA-2016-D-0643-0001). IGBA’s position is aligned with the key comments of the Biosimilar Medicines Group, a sector group of Medicines for Europe, which have been submitted separately.

Read More

 

 

 

 

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

c/o Interexperts SA
Rue des Pierres-du-Niton 17
1207 Geneva, Switzerland

Telephone: +32 (0)2 5346607
E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or 
This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site